Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
Series Vol. 6 , 03 August 2023
Open
Access | Article
Efficacy and mechanism of cyclin-dependent kinase inhibitors against cancer
* Author to whom correspondence should be addressed.
Abstract
This paper focuses on an overview of the development progress of different cyclin-dependent kinase (CDK) inhibitors. The CDKS are a group of kinases that are indispensable in the cell cycle. However, when it comes to cancer, the cell cycle is not healthy which causes malignancy of the cell that is able to mitosis infinitely. Considering the CDK are a group of molecules that is fundament during mitosis, researchers have developed its inhibitors to inhibit the effect that it has during the cell cycle to postpone the growth of cancer and lead to cancer cell apoptosis. This paper targets on the CDK inhibitors of pan-CDK, CDK4/6, 7, 9, and 12, also introducing their development history and current stages in clinical trials, as well as the drugs related to these CDK inhibitors that are FDA-approved for cancer treatment. In addition, the paper also introduces the future potentials of CDK inhibitors in the treatment and therapy of cancer-related diseases.
Keywords
CDK, breast cancer, combination therapy
References
1. Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, Zheng Q, Cai C. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021 May 15;11(5):1913-1935. PMID: 34094661; PMCID: PMC8167670.
2. Scott SC, Lee SS, Abraham J. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. Semin Oncol. 2017 Dec;44(6):385-394.
3. Sava, G.P., Fan, H., Coombes, R.C. et al. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev 39, 805–823 (2020).
4. Boffo, S., Damato, A., Alfano, L. et al. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res 37, 36 (2018).
5. Hui Liu, Kangding Liu, Zigang Dong; Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery. Cancer Res 1 January 2021; 81 (1): 18–26
6. Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, Yajun Duan, Jihong Han, Qin Wang, and Chenzhong Liao. Journal of Medicinal Chemistry 2022 65 (9), 6356-6389.
7. Iwata, H. Clinical development of CDK4/6 inhibitor for breast cancer. Breast Cancer 25, 402–406 (2018).
8. Jin Yuan, Xiaoyang Li, Shengji Yu, CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1877, Issue 2, 2022, 188680, ISSN 0304-419X.
9. Fatima Morales & Antonio Giordano (2016) Overview of CDK9 as a target in cancer research, Cell Cycle, 15:4, 519-527.
10. Paculová, H., Kohoutek, J. The emerging roles of CDK12 in tumorigenesis. Cell Div 12, 7 (2017).
11. Ruijun Tang, Jing Liu, Shuyao Li, Junjie Zhang, Chunhong Yu, Honglu Liu, Fang Chen, Lu Lv, Qian Zhang, Kai Yuan & Hao Shao (2022) A patent and literature review of CDK12 inhibitors, Expert Opinion on Therapeutic Patents, 32:10, 1055-1065.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230169
- Copyright
- © 2023 The Author(s)
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited